CIK Cell Therapy Development Services for Cancer
Alfa Cytology is committed to advancing the progress of cancer cell therapies. Our research includes a comprehensive exploration of the mechanism of action, therapeutic efficacy, and safety of CIK Cell therapy, to provide tailored preclinical research services for the development of CIK cell cancer therapy.
Introduction to CIK Cell Therapy
Cytokine-induced killer (CIK) cells are a mixture of T cells with TCR- and NK-mediated cancer-recognition functions and have significant cytotoxic activity against tumor cells. These cells are generated in vivo by stimulating and expanding peripheral blood mononuclear cells (PBMC) with cytokines such as interferon-gamma (IFN-γ), interleukin-2 (IL-2), and anti-CD3 antibodies. CIK cells are broadly specific for tumor cells and have a memory profile that has the potential to produce long-lasting antitumor responses. CIK cell therapy is already licensed in several countries, including Germany. Compared to other cancer immunotherapies, CIK therapy has several key advantages as shown below.
- As a heterogeneous cell population, CIK cells can attack multiple tumor targets and exhibit enhanced cytotoxicity against tumors.
- CIK cells exhibit MHC-independent tumor targeting and the ability to reduce allogeneic reactivity across the MHC barrier.
- CIK cells are inexpensive and clinically relevant doses can be easily achieved with standard culture protocols.
- The ease of culture of CIK cells offers the possibility to enhance their cytotoxic potential within the framework of controlled experiments.
Fig.1 Cancer recognition and anti-cancer activity of CIK cells. (Li, C. M. Y., et al., 2023)
Our Services
Services Provided for CIK Cell Therapy Development
To address the multifaceted challenges inherent in the development of CIK cell therapy, Alfa Cytology offers a suite of scientific services designed to address the impediments and optimize therapeutic outcomes. Our services focus on the following key programs.
Optimizing CIK Cell Expansion
For specific tumor types, Alfa Cytology offers customized CIK cell expansion protocols. We ensure cell yield, purity and potency by optimizing cell culture conditions and growth factors.
Enhanced CIK Cell Tumor Specificity
Enhanced tumor specificity of CIK cells through molecular techniques such as genetic engineering and surface marker targeting to minimize off-target effects and ensure targeted and effective therapeutic approaches.
CIK Cell Characterization
Advanced flow cytometry, gene expression profiling and functional analysis are used to analyze the phenotype, cytokine secretion profile and cytotoxic activity of CIK cells to ensure the consistency and potency of the final cell product.
CIK Cell Therapy Assessment
Perform rigorous in vivo efficacy assessments using advanced preclinical models and imaging techniques, and in-depth mechanistic studies to elucidate the interaction between CIK cells and the tumor microenvironment.
Workflow of CIK Cell Therapy Development
Antigen Loading & Maturation
Immunogenicity Assessment of Vaccines
Translational Research
Quality Control & Characterization
In Vivo Efficacy Studies
Alpha Cytology is your reliable partner in advancing the research and development of CIK cell therapies by providing comprehensive solutions. Our services are available to clients in diverse research areas such as oncology, infectious diseases, and autoimmune disorders, and are designed to accelerate the progress of your program and lead the way in innovation. Contact us today to learn how we can be involved in your project.
Reference
- Li, C. M. Y., et al.; (2023). Clinical application of cytokine-induced killer (CIK) cell therapy in colorectal cancer: Current strategies and future challenges. Cancer Treatment Reviews, 102665.
! For research use only.
Related Services
